[关键词]
[摘要]
目的 探究复方鲜竹沥液联合异丙托溴铵治疗慢性阻塞性肺疾病急性加重期的疗效。方法 选取2015年1月-2016年6月天津市滨海新区大港医院呼吸科收治的慢性阻塞性肺疾病急性加重期患者321例,随机分为对照组(160例)和治疗组(161例)。对照组患者给予异丙托溴铵气雾剂,2揿/次,2次/d。治疗组在对照组的治疗基础上口服复方鲜竹沥液,20 mL/次,2次/d。两组患者均连续治疗7 d。观察两组的临床疗效,同时比较两组治疗前后肺功能指标、血气分析指标、炎症因子水平的变化情况。结果 治疗后,对照组和治疗组的总有效率分别为86.88%、96.89%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者一秒用力呼气容积(FEV1)、一秒用力呼气容积/用力肺活量(FEV1/FVC)及最大呼气中期流量(MMEF)、氧分压(pO2)均比治疗前显著升高,二氧化碳分压(pCO2)显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组FEV1、FEV1/FVC、MMEF、pO2均显著高于对照组,pCO2低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者肿瘤坏死因子-α(TNF-α)、人白细胞介素6(IL-6)、C反应蛋白(CRP)均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组TNF-α、IL-6、CRP水平显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论 复方鲜竹沥液联合异丙托溴铵治疗慢性阻塞性肺疾病急性加重期具有显著的临床疗效,可显著改善肺功能和血气分析指标,降低炎症因子水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To explore the clinical efficacy of Compound Xianzhuli Liqulid combined with isopropyl bromide in treatment of acute exacerbations of chronic obstructive pulmonary disease. Methods Patients (321 cases) with acute exacerbations of chronic obstructive pulmonary disease in Department of Respiratory of Dagang Hospital of Tianjin Binhai New Area from January 2001 to June 2016 were randomly divided into control (160 cases) and treatment (161 cases) groups. Patients in the control group were administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were po administered with Compound Xianzhuli Liqulid on the basis of the control group, 20 mL//time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the changes of lung function indexes, blood gas analysis indexes and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.88% and 96.89%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1, FEV1/FVC, MMEF, and pO2 in two groups significantly increased, but pCO2 significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, FEV1, FEV1/FVC, MMEF, and pO2 in the treatment group were higher than those in the control group, and there was difference between two groups (P<0.05). After treatment, TNF-α, IL-6, and CRP significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, TNF-α, IL-6, and CRP in the treatment group were lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Compound Xianzhuli Liqulid combined with isopropyl bromide has a significant effect in treatment of acute exacerbations of chronic obstructive pulmonary disease, and can significantly improve lung function and blood gas analysis indexes, and also can reduce inflammatory factor levels, which has a certain clinical application value.
[中图分类号]
[基金项目]